Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Morphic Holding, Inc. (MORF) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023 -Reported positive topline results from EMERALD-1study of MORF-057 in ulcerative colitis-"
03/01/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Press release issued by Morphic Holding, Inc. regarding its financial results for the quarter ended September 30, 2020"
08/10/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
Docs: "Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results"
02/27/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/12/2019 8-K Quarterly results
Docs: "Morphic Announces Corporate Highlights and Second Quarter 2019 Financial Results -Successful IPO provides more than $100 million in gross proceeds to advance leading oral integrin development pipeline and MInT discovery platform - Company remains on track to file INDs for its two lead programs WALTHAM, Mass., Aug. 12, 2019 — Morphic Therapeutic , a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the second quarter of 2019. “Morphic's goal is to unlock the broad medical potential of integrin biology with the first orally administered, small-molecule integrin therapeutics. Our recent initial public offering added nearly $100 million to an already stron..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy